{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T19:49:56Z","timestamp":1771789796882,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ad.2022.08.015","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T18:45:16Z","timestamp":1661625916000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain"],"prefix":"10.1016","volume":"114","author":[{"given":"E.","family":"Artime","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"D\u00edaz-Cerezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Huete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Hern\u00e1ndez-Subir\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lledo-Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sicras-Mainar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2022.08.015_bib0170","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.08.015_bib0175","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/1346-8138.13392","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2016","volume":"43","author":"Saeki","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2022.08.015_bib0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.18176\/jiaci.0339","article-title":"Prevalence of severe atopic dermatitis in adults and children in a health area of Madrid, Spain","volume":"29","author":"Barroso","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.ad.2022.08.015_bib0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/21556660.2019.1619570","article-title":"Epidemiology of atopic dermatitis in Europe","volume":"8","author":"Kowalska-Ol\u0119dzka","year":"2019","journal-title":"J Drug Assess"},{"key":"10.1016\/j.ad.2022.08.015_bib0190","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2022.08.015_bib0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ad.2017.09.003","article-title":"Economic impact of atopic dermatitis in adults: a population-based study (IDEA study)","volume":"109","author":"Sicras-Mainar","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.08.015_bib0200","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdv.14058","article-title":"Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life","volume":"31","author":"Chernyshov","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.08.015_bib0205","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol In Practice"},{"key":"10.1016\/j.ad.2022.08.015_bib0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/25785826.2019.1628467","article-title":"Future trends in the treatment of atopic dermatitis","volume":"42","author":"Igawa","year":"2019","journal-title":"Immunol Med"},{"key":"10.1016\/j.ad.2022.08.015_bib0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s13555-018-0258-x","article-title":"Treatment of atopic dermatitis with biologic drugs","volume":"8","author":"Fabbrocini","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2022.08.015_bib0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1203475417733460","article-title":"A treatment algorithm for moderate to severe atopic dermatitis in adults","volume":"22","author":"Lynde","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2022.08.015_bib0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjd.19428","article-title":"Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study","volume":"184","author":"Pereyra-Rodriguez","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.08.015_bib0230","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2147\/TCRM.S226456","article-title":"Severe atopic dermatitis in Spain: a real-life observational study","volume":"15","author":"Sicras-Mainar","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ad.2022.08.015_bib0235","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ad.2011.12.008","article-title":"Actualizaci\u00f3n en dermatitis at\u00f3pica. Propuesta de algoritmo de actuaci\u00f3n","volume":"104","author":"Garnacho-Saucedo","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.08.015_bib0240","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"Validation and representativeness of the spanish big-pac database: integrated computerized medical records for research into epidemiology, medicines and health resource use (Real Evidence)","volume":"22","author":"Sicras-Mainar","year":"2019","journal-title":"Value Heal"},{"key":"10.1016\/j.ad.2022.08.015_bib0245","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD). https:\/\/www.who.int\/standards\/classifications\/other-classifications\/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses [accessed 23.9.21]."},{"key":"10.1016\/j.ad.2022.08.015_bib0250","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/jdv.14880","article-title":"Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine","volume":"32","author":"Law Ping Man","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.08.015_bib0255","unstructured":"Bot Plus from the General Council of the Spanish Official College of Pharmacists. https:\/\/botplusweb.portalfarma.com\/."},{"key":"10.1016\/j.ad.2022.08.015_bib0260","unstructured":"Instituto Nacional de Estad\u00edstica (INE). https:\/\/www.ine.es\/consul\/serie.do?d=true&s=EAES291."},{"key":"10.1016\/j.ad.2022.08.015_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210517","article-title":"Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis","volume":"14","author":"Armstrong","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2022.08.015_bib0270","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/jdv.16003","article-title":"The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada","volume":"34","author":"de Bruin-Weller","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.08.015_bib0275","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/09546634.2020.1866741","article-title":"Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study","volume":"32","author":"de Bruin-Weller","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.08.015_bib0280","unstructured":"Dupilumab approval in 2020. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-dupilumab-Dupixent-dermatitis-atopica-v2.pdf?x22584."},{"key":"10.1016\/j.ad.2022.08.015_bib0285","doi-asserted-by":"crossref","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov doi:10.1038\/s41573-021-00266-6.","DOI":"10.1038\/s41573-021-00266-6"},{"key":"10.1016\/j.ad.2022.08.015_bib0290","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjd.17715","article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries","volume":"181","author":"Vermeulen","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.08.015_bib0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00005-018-0521-y","article-title":"Systemic treatment for severe atopic dermatitis","volume":"67","author":"Giavina-Bianchi","year":"2019","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.ad.2022.08.015_bib0300","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/cea.12495","article-title":"Pathogenesis of atopic dermatitis","volume":"45","author":"Peng","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ad.2022.08.015_bib0305","first-page":"133","article-title":"Diagnosis and management of moderate to severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Cli","volume":"153","author":"Calzavara Pinton","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.08.015_bib0310","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","article-title":"Burden of illness in adults with atopic dermatitis: analysis of national health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom","volume":"81","author":"Eckert","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.08.015_bib0315","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","article-title":"Costs and healthcare utilisation of patients with heart failure in Spain","volume":"20","author":"Escobar","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ad.2022.08.015_bib0320","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jad.2021.08.036","article-title":"Economic impact of treatment-resistant depression: a retrospective observational study","volume":"295","author":"P\u00e9rez-Sola","year":"2021","journal-title":"J Affect Disord"},{"key":"10.1016\/j.ad.2022.08.015_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.nefroe.2022.01.008","article-title":"Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain","author":"Escobar","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.ad.2022.08.015_bib0330","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s12325-021-01773-z","article-title":"Real-world use of insulin glargine U100 and U300 in insulin-na\u00efve patients with type 2 diabetes mellitus: DosInGlar study","volume":"38","author":"Duque","year":"2021","journal-title":"Adv Ther"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731022007591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731022007591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:14:43Z","timestamp":1757553283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731022007591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0001731022007591"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2022.08.015","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2022.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}